Wenying Li
About Wenying Li
Wenying Li is the Scientific Director - DMPK Project Representative & Head of Dev. Biotransformation at Bristol Myers Squibb, with a PhD in Organic Chemistry from Rice University and extensive experience in regulatory filings.
Company
Wenying Li is currently employed at Bristol Myers Squibb, a notable global biopharmaceutical company. As of now, she holds the position of Scientific Director - DMPK Project Representative & Head of Development Biotransformation.
Title
Wenying Li serves as the Scientific Director - DMPK Project Representative & Head of Development Biotransformation at Bristol Myers Squibb. Her role involves directing key projects and overseeing development in the domain of biotransformation.
Education and Expertise
Wenying Li holds a PhD in Organic Chemistry from Rice University, where she focused on advanced organic chemistry. She also earned both MS and BS degrees in Physical Chemistry from Xiamen University. Her areas of specialization include NCPK/human ADME/DDI assessment, with significant contributions to regulatory filings like IND, CTA, and NDA.
Background
Wenying Li has an extensive background in the pharmaceutical industry, with a long tenure at Bristol Myers Squibb spanning 26 years. She progressed through various roles, starting as a Research Investigator and advancing to Scientific Associate Director, before eventually becoming the Scientific Director - DMPK Project Representative & Head of Development Biotransformation.
Achievements
Wenying Li has considerable experience in contributing to regulatory filings, including IND, CTA, and NDA, for NCPK/human ADME/DDI assessments. Her extensive tenure at Bristol Myers Squibb highlights her dedication and expertise in the field of drug metabolism and pharmacokinetics.